South Korea · Delayed Price · Currency is KRW Whan In Pharm Statistics
Total Valuation
Whan In Pharm has a market cap or net worth of KRW 190.38 billion. The enterprise value is 124.31 billion.
| Market Cap | 190.38B |
| Enterprise Value | 124.31B |
Important Dates
The next estimated earnings date is Thursday, October 29, 2026.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Whan In Pharm has 18.48 million shares outstanding. The number of shares has increased by 14.39% in one year.
| Current Share Class | 18.48M |
| Shares Outstanding | 18.48M |
| Shares Change (YoY) | +14.39% |
| Shares Change (QoQ) | -0.33% |
| Owned by Insiders (%) | 23.42% |
| Owned by Institutions (%) | 12.19% |
| Float | 14.15M |
Valuation Ratios
The trailing PE ratio is 8.80 and the forward PE ratio is 8.69. Whan In Pharm's PEG ratio is 0.34.
| PE Ratio | 8.80 |
| Forward PE | 8.69 |
| PS Ratio | 0.70 |
| PB Ratio | 0.45 |
| P/TBV Ratio | 0.46 |
| P/FCF Ratio | 12.64 |
| P/OCF Ratio | 10.78 |
| PEG Ratio | 0.34 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 3.76, with an EV/FCF ratio of 8.25.
| EV / Earnings | 6.08 |
| EV / Sales | 0.45 |
| EV / EBITDA | 3.76 |
| EV / EBIT | 5.35 |
| EV / FCF | 8.25 |
Financial Position
The company has a current ratio of 4.26, with a Debt / Equity ratio of 0.00.
| Current Ratio | 4.26 |
| Quick Ratio | 2.44 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.02 |
| Debt / FCF | 0.04 |
| Interest Coverage | 645.79 |
Financial Efficiency
Return on equity (ROE) is 5.08% and return on invested capital (ROIC) is 4.96%.
| Return on Equity (ROE) | 5.08% |
| Return on Assets (ROA) | 3.06% |
| Return on Invested Capital (ROIC) | 4.96% |
| Return on Capital Employed (ROCE) | 5.24% |
| Weighted Average Cost of Capital (WACC) | 5.20% |
| Revenue Per Employee | 433.40M |
| Profits Per Employee | 32.41M |
| Employee Count | 631 |
| Asset Turnover | 0.60 |
| Inventory Turnover | 1.86 |
Taxes
In the past 12 months, Whan In Pharm has paid 5.10 billion in taxes.
| Income Tax | 5.10B |
| Effective Tax Rate | 19.97% |
Stock Price Statistics
The stock price has decreased by -4.63% in the last 52 weeks. The beta is 0.17, so Whan In Pharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | -4.63% |
| 50-Day Moving Average | 10,054.60 |
| 200-Day Moving Average | 10,579.30 |
| Relative Strength Index (RSI) | 54.40 |
| Average Volume (20 Days) | 35,874 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Whan In Pharm had revenue of KRW 273.47 billion and earned 20.45 billion in profits. Earnings per share was 1,170.89.
| Revenue | 273.47B |
| Gross Profit | 98.96B |
| Operating Income | 22.31B |
| Pretax Income | 25.56B |
| Net Income | 20.45B |
| EBITDA | 32.16B |
| EBIT | 22.31B |
| Earnings Per Share (EPS) | 1,170.89 |
Balance Sheet
The company has 66.64 billion in cash and 567.99 million in debt, with a net cash position of 66.07 billion or 3,574.68 per share.
| Cash & Cash Equivalents | 66.64B |
| Total Debt | 567.99M |
| Net Cash | 66.07B |
| Net Cash Per Share | 3,574.68 |
| Equity (Book Value) | 425.47B |
| Book Value Per Share | 23,044.77 |
| Working Capital | 183.73B |
Cash Flow
In the last 12 months, operating cash flow was 17.67 billion and capital expenditures -2.60 billion, giving a free cash flow of 15.06 billion.
| Operating Cash Flow | 17.67B |
| Capital Expenditures | -2.60B |
| Depreciation & Amortization | 9.84B |
| Net Borrowing | -538.16M |
| Free Cash Flow | 15.06B |
| FCF Per Share | 814.87 |
Margins
Gross margin is 36.19%, with operating and profit margins of 8.16% and 7.48%.
| Gross Margin | 36.19% |
| Operating Margin | 8.16% |
| Pretax Margin | 9.34% |
| Profit Margin | 7.48% |
| EBITDA Margin | 11.76% |
| EBIT Margin | 8.16% |
| FCF Margin | 5.51% |
Dividends & Yields
This stock pays an annual dividend of 300.00, which amounts to a dividend yield of 2.87%.
| Dividend Per Share | 300.00 |
| Dividend Yield | 2.87% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 27.11% |
| Buyback Yield | -14.39% |
| Shareholder Yield | -11.52% |
| Earnings Yield | 10.74% |
| FCF Yield | 7.91% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 14, 2010. It was a forward split with a ratio of 2.
| Last Split Date | Apr 14, 2010 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Whan In Pharm has an Altman Z-Score of 4.15 and a Piotroski F-Score of 4.
| Altman Z-Score | 4.15 |
| Piotroski F-Score | 4 |